# Association between serum leucine-rich alpha-2-glycoprotein levels and characteristic enteroclysis findings in small intestinal Crohn’s disease

**Authors:** Masayuki Fukata, Shu Kikuta, Kazuyo Okayama, Akira Sonoda, Soh Okano, Kiyohito Unuma

PMC · DOI: 10.1093/crocol/otag012 · Crohn's & Colitis 360 · 2026-02-18

## TL;DR

This study finds that higher levels of a protein called LRG in the blood are linked to specific signs of Crohn’s disease in the small intestine seen on a special imaging test.

## Contribution

The study demonstrates that serum LRG is a better biomarker than CRP for detecting specific Crohn’s disease lesions in the small intestine.

## Key findings

- Serum LRG levels were significantly higher in patients with Crohn’s disease lesions compared to those without.
- LRG showed better detection accuracy than CRP for longitudinal ulcers and strictures in Crohn’s disease.
- LRG levels were not influenced by disease extent or prior bowel resection.

## Abstract

Enteroclysis provides a whole picture of mucosal and wall-structural information that is advantageous in assessing small intestinal Crohn’s disease (CD). Leucine-rich alpha-2-glycoprotein (LRG) is an acute-phase protein that has been shown to be increased in active CD. We sought to explore the association of LRG with the presence of typical CD findings in enteroclysis.

Patients with small intestinal CD whose serum LRG and C-reactive protein (CRP) were measured within 30 days before or after enteroclysis were selected, and were categorized by the presence of longitudinal ulcer, cobblestone appearance, and stricture/narrowing. Levels of LRG were compared by the type and the extent of lesions. Detection performances of LRG and CRP were compared for the presence of each type of lesion.

Serum LRG levels were significantly higher in patients who had enteroclysis findings than patients with no findings (23.5 ± 9.2 vs. 12.8 ± 3.0 μg/dL, P < .00001). The level of LRG was not affected by disease extent or history of bowel resection. LRG over 16.3 μg/dL had good detection accuracy for the presence of CD lesions with an area under the receiver operating characteristic curve of 0.85 (95% confidence interval: 0.75-0.95). The association of LRG with the presence of CD-specific lesions was significantly higher than CRP, especially for the presence of stricture/narrowing (AUC: 0.82 vs. 0.67, P = .005) and longitudinal ulcer (AUC: 0.93 vs. 0.80, P = .017).

Elevation of serum LRG is associated with the presence of typical CD lesions in the small intestine that may be found in entericlysis.

Graphical Abstract

## Linked entities

- **Diseases:** Crohn’s disease (MONDO:0005011)

## Full-text entities

- **Genes:** LRG1 (leucine rich alpha-2-glycoprotein 1) [NCBI Gene 116844] {aka HMFT1766, LRG}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** IBD (MESH:D015212), mucosal lesions (MESH:D009059), jejuno-ileitis (MESH:D007079), aphthous ulcers (MESH:D013281), colonic lesions (MESH:D003108), fistulas (MESH:D005402), deformity of the intestinal tract (MESH:D007410), stenosis (MESH:D003251), small (MESH:D018288), inflammation (MESH:D007249), mucosal ulcers (MESH:D014456), abdominal pain (MESH:D015746), weight loss (MESH:D015431), perianal disease (MESH:D000694), CD lesion (MESH:D003424)
- **Chemicals:** barium (MESH:D001464), budesonide (MESH:D019819), Ustekinumab (MESH:D000069549), 5-ASA (MESH:D019804), Thioprine (-), Vedolizumab (MESH:C543529), barium sulfate (MESH:D001466)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12962800/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962800/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12962800/full.md

---
Source: https://tomesphere.com/paper/PMC12962800